ArticleBMC pulmonary medicine2025
Chronic rhinosinusitis is a risk factor for interstitial lung disease in Sjogren's syndrome.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) is a leading cause of morbidity and mortality in Sjögren's syndrome (SS), but its risk factors remain unclear. Although SS affects both the upper and lower respiratory epithelium, it is unknown whether this occurs simultaneously or separately. In other autoimmune conditions-such as eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis-upper airway disease precedes lower lung involvement by months or even years. We hypothesized that chronic rhinosinusitis (CRS), as an upper airway disease, may be a risk factor for ILD in SS.
methodsWe analyzed the TriNetX Research Network database to compare incident ILD in SS patients with or without CRS. Patients with pre-existing ILD or CRS were excluded, and all participants were being treated with Sjögren's related immunosuppression or sicca therapies. Incident ILD and risk ratios (RR) were calculated at 5 and 10 years after adjusting for important confounding variables, such as age, gender, race, comorbid conditions, and other risk factors.
resultsIn matched cohorts, overall risk for developing ILD was significantly higher in patients with CRS. At 5 years, incidence of ILD was 2.56% in patients with CRS versus 1.66% in those without CRS (adjusted RR 1.57, p = 0.01, 95% CI: 1.09-2.27). Likewise, at 10 years, the ILD incidence was 3.01% in patients with CRS versus 1.96% in those without CRS (adjusted RR 1.53, p = 0.01, 95% CI: 1.09-2.13).
conclusionOur results suggest SS patients with CRS are at higher risk for developing ILD, indicating a possible need for more intensive screening in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.